Zeyu Liu

Zeyu Liu

Auto-generated profile, based on publicly available information

Zeyu Liu

Shenzhen Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in British Journal of Anaesthesia
Verified
Journal Article
Open access
ZLZeyu Liu
Zeyu Liu
JZJinquan Zhang
Jinquan Zhang
XCXiaona Chen
Xiaona Chen
ZSZiqi Sun
Ziqi Sun
JCJiabo Chen
Jiabo Chen
QLQuan Li
Quan Li
Tumour-associated macrophages (TAMs), which are frequently associated with cancer-related death in humans, play crucial roles in the metastasis of tumours, including lung cancer. However, whether lidocaine affects TAMs and exerts antimetastatic effects on non-small cell lung cancer remains unclear. Lung cancer cells were treated directly with lidocaine or cocultured with lidocaine-treated TAMs. The effect of lidocaine on lung cancer metastasis was assessed by performing experiments in C57BL/6 mice and BALB/c nude mice in vivo. The migration and proliferation of lung cancer cells were evaluated by wound healing, transwell, and CCK-8 assays. Furthermore, changes in macrophage polarisation were assessed via reverse transcription-quantitative polymerase chain reaction and flow cytometry analysis. Lidocaine suppressed tumour metastasis in C57BL/6 mice (P<0.01) but not in BALB/c nude mice. When macrophages were depleted by clodronate liposomes in C57BL/6 mice, the antimetastatic effect of lidocaine was abrogated. However, the antimetastatic effect of lidocaine was observed in BALB/c nude mice simultaneously injected with both lung cancer cells and TAMs (P<0.001). Lidocaine attenuated the polarisation of TAMs toward the M2b subtype (P<0.05) by inhibition of the activation of the protein kinase B/cAMP-response element binding protein pathway. Our results indicate that lidocaine attenuates tumour metastasis through modulation of M2b-polarised TAMs in non-small cell lung cancer, providing a mechanistic basis for the potential application of anaesthetics in lung cancer patients.

1 January 2025 in Analytical Cellular Pathology
Verified
Journal Article
Open access
CZChuangjie Zheng
Chuangjie Zheng
YRYingfang Ren
Yingfang Ren
KWKe Wang
Ke Wang
XCXinrong Chen
Xinrong Chen
JTJiahao Tao
Jiahao Tao
LZLinzhu Zhai
Linzhu Zhai
Background: Non–small‐cell lung cancer remains the leading cause of cancer‐related deaths globally, and epidermal growth factor receptor mutations have been identified as crucial drivers of the disease. Encouragingly, epidermal growth factor receptor tyrosine kinase inhibitors have demonstrated promising clinical outcomes. Nonetheless, the emergence of resistance to third‐generation EGFR‐TKIs like osimertinib and almonertinib is an inevitable challenge. Methods: In this study, we generated almonertinib‐resistant cell lines from H‐1975 and HCC827 lung cancer cell lines. We utilized various assays, including cell proliferation assays, hematoxylin and eosin staining, and cell cycle assays, to investigate the characteristics of drug‐resistant cells. Additionally, we performed RNA transcriptome sequencing to identify differentially expressed genes (DEGs) in almonertinib‐resistant cells. To further expand our analysis, we obtained sequencing data of osimertinib‐resistant cells from the Gene Expression Omnibus (GEO) dataset and identified DEGs in these cells. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to assess the biological functions and signaling mechanisms associated with DEGs. Furthermore, the survival prognosis and immune cell infiltration of common differentially expressed genes (co‐DEGs) in osimertinib—and almonertinib‐resistant cells were analyzed, and the expression of a co‐DEG ( IGFBP7 ) was verified through quantitative reverse transcriptase polymerase chain reaction (qPCR) and western blotting (WB) assays. Gene knockdown plasmids were constructed for cell transfection, and the invasive ability of resistant cells was assessed using a Transwell assay following the knockdown of IGFBP7 . Results: Experimental cell counting kit–8 cytotoxicity studies revealed intriguing findings regarding drug resistance in lung cancer cells. Specifically, the IC 50 values and resistance factors of H‐1975 and HCC827 cells were found to be 1.9 nM and 833.58 and 2.2 nM and 631.95, respectively. In addition to these quantitative results, comparative observations of the cell morphology and cell cycle revealed significant alterations in drug‐resistant cells. Transcriptome sequencing analysis identified 220 DEGs between H‐1975 and H‐1975/AR and 736 DEGs between HCC827 and HCC827/AR. Interestingly, screening of overlapping DEGs with osimertinib‐resistant cells in the GEO database identified some common genes, such as IGFBP7 and RFTN1 , which were found to be associated with the improved prognosis of non–small–cell lung cancer by survival analysis. Furthermore, GO analysis and KEGG pathway enrichment analysis revealed different pathway changes in different drug‐resistant cells. Survival analysis indicated that a higher expression of co‐DEGs ( IGFBP7 , RFTN1 ) was associated with a more favorable prognosis. Furthermore, IGFBP7 expression is strongly associated with infiltration levels of CD8+ T cells, Tregs, and macrophage cells in lung adenocarcinoma. Molecular biology experiments confirmed that the mRNA and protein expression level of IGFBP7 were over‐expressed in almonertinib‐resistance cells. H‐1975/AR cells were transfected with si‐ IGFBP7 , and the results of transfection were verified at the mRNA and protein levels. After knocking down gene expression, the IC 50 of the cells was 0.3 ± 0.02 µM, which was significantly lower than that of untransfected cells. Additionally, the invasion of cells in the knockdown group was repressed. Conclusions: These findings indicated that almonertinib and osimertinib exhibited distinct resistance mechanisms in vitro, underscoring the need for tailored treatment approaches.